A phase 1 trial of LSAM-Cisplatin in children diagnosed with Diffuse Intrinsic Pontine Glioma
Latest Information Update: 31 Dec 2025
At a glance
- Drugs Cisplatin (Primary)
- Indications Diffuse intrinsic pontine glioma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 31 Dec 2025 New trial record
- 11 Dec 2025 According to a Nanology media release, NanOlogy is completing Investigational New Drug (IND) enabling studies required by the U.S. Food and Drug Administration (FDA). Upon completion of these studies, the company plans to submit an IND application for LSAM-Cisplatin to treat malignant neoplasms of the brain including DIPG. Subject to FDA allowance to proceed, company aims to initiate a clinical trial in late 2026.